Related Experiment Video
Updated: Jan 21, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
Published on: October 17, 2013
Novel Delivery Systems for Checkpoint Inhibitors
Purushottam Lamichhane1, Rahul Deshmukh2, Julie A Brown1
1School of Dental Medicine, Lake Erie College of Osteopathic Medicine, 4800 Lakewood Ranch Blvd, Bradenton, FL 34211, USA.
Abstract:
Checkpoint inhibition (CPI) therapies have been proven to be powerful clinical tools in treating cancers. FDA approvals and ongoing clinical development of checkpoint inhibitors for treatment of various cancers highlight the immense potential of checkpoint inhibitors as anti-cancer therapeutics. The occurrence of immune-related adverse events, however, is a major hindrance to the efficacy and use of checkpoint inhibitors as systemic therapies in a wide range of patients. Hence, methods of sustained and tumor-targeted delivery of checkpoint inhibitors are likely to improve efficacy while also decreasing toxic side effects. In this review, we summarize the findings of the studies that evaluated methods of tumor-targeted delivery of checkpoint inhibitors, review their strengths and weaknesses, and discuss the outlook for therapeutic use of these delivery methods.
Insights
Checkpoint inhibition (CPI) therapies offer powerful cancer treatment options. Targeted delivery methods aim to enhance efficacy and reduce side effects for broader patient application.
Area of Science:
- Oncology
- Immunotherapy
- Drug Delivery Systems
Background:
- Checkpoint inhibition (CPI) therapies are effective cancer treatments with significant clinical potential.
- Immune-related adverse events are a major limitation, hindering the efficacy and widespread use of CPI.
- Developing methods for sustained and tumor-targeted delivery of CPI is crucial for improving outcomes.
Purpose of the Study:
- To review studies evaluating tumor-targeted delivery of checkpoint inhibitors.
- To analyze the strengths and weaknesses of various delivery methods.
- To discuss the future therapeutic potential of these delivery strategies.
Main Methods:
- Literature review of studies on targeted delivery of checkpoint inhibitors.
- Analysis of efficacy and safety data from evaluated methods.
- Synthesis of findings to assess the outlook for therapeutic applications.
Main Results:
- Various methods for tumor-targeted delivery of CPI have been investigated.
- Targeted delivery shows promise in enhancing anti-cancer efficacy.
- Reduced systemic toxicity is a key benefit of targeted delivery approaches.
Conclusions:
- Tumor-targeted delivery of checkpoint inhibitors is a promising strategy.
- These methods have the potential to improve therapeutic efficacy and minimize adverse events.
- Further research and development are warranted for clinical translation.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...
Classification of Systems-I
Homogeneity dictates that if an input x(t) is multiplied by a constant c, the output y(t) is multiplied by the same constant. Mathematically, this is expressed as:

